The EPS projection of Bio-Techne Corp (NASDAQ:TECH) for quarter ended 2016-09-30 is $0.77. Last week, the projection for EPS was $0.77 against target of $0.77, a month earlier. While 2-months ago, this projection was $0.77 versus forecast of $0.77a quarter months earlier, posting a deviation of -0.03%.
Bio-Techne Corp (NASDAQ:TECH) posted that 18 days earlier, the share price was revised 0 times on upside. In addition, negative revisions were 0.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 0 and 0. While in last 120 and 90 days, positive revisions were 0, and 0, correspondingly.
The per-share earnings downgrade for Bio-Techne Corp (NASDAQ:TECH) in the preceding 30 and 120 were 0 and 1. While in 60 and 90 days were 1, and 1, in that order.
Bio-Techne Corp (NASDAQ:TECH) EPS target was $0.77 for the quarter closed 3. It was based on 3 calls. As on 2016-05-03 the EPS was $0.97. The change was $0.12, posting a deviation of 14.12%. The price projections gave a standard deviation of 0.03.
Quarterly Sales Estimates
Bio-Techne Corp (NASDAQ:TECH) sales prediction for the fiscal 2017 stands at $138.008 and the median estimate is at $138.25. Almost 5 analysts gave sales target.
Among this, the highest sales estimate is $142.08 while the lowest target is $132.53 showing standard deviation of 3.67%.
As many as 5 analysts have positive sales targets revision while 5 reduced sales estimates, posting a deviation of 1.002%.
Last month, 5 experts have positive sales number revision. Also, 5 research groups lowered the sales projections, posting a deviation of 1.002%.
A quarter ago, 5 hiked sales target and 5 reduced sales forecast, posting a deviation of 2.26%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...